Adherence to coronary artery disease secondary prevention medicines: exploring modifiable barriers
Open Access
- 3 July 2019
- journal article
- research article
- Published by BMJ in Open Heart
- Vol. 6 (2) , e000997
Abstract
Background: Non-adherence to secondary prevention medicines (SPMs) among patients with coronary artery disease (CAD) remains a challenge in clinical practice. This study attempted to identify actual and potential modifiable barriers to adherence that can be addressed in cardiology clinical practice. Methods: This was a cross-sectional, postal survey-based study of the medicines-taking experience of patients with CAD treated at a secondary/tertiary care centre. All participants had been on SPM for ≥3 months. Results: In total, 696 eligible patients were sent the survey and 503 responded (72.3%). The median age was 70 years, and 403 (80.1%) were male; the median number of individual daily doses of all medicines was 6. The rate of non-adherence to at least one SPM was 43.5% (n=219), but 53.3% of reported non-adherence was to only one SPM. Statins contributed to 66.7% and aspirin to 61.7% of overall non-adherence identified by the Single Question (SQ) tool. In 30.8% of non-adherent patients (n=65), this was at least partly intentional. Barriers included forgetfulness (84.9%; n=186), worry that medicines will do more harm than good (33.8%; n=74), feeling hassled about medicines taking (18.7%; n=41), feeling worse when taking medicines (14.2%; n=31) and not being convinced of the benefit of medicines (9.1%; n=20). In a multivariate analysis, modifiable factors associated with overall non-adherence included being prescribed aspirin (OR: 2.22; 95% CI: 1.18 to 4.17), having specific concern about SPM (OR: 1.12; 95% CI: 1.07 to 1.18) and issues with repeat prescriptions (OR: 2.48; 95% CI: 1.26 to 4.90). Different factors were often associated with intentional versus unintentional non-adherence. Conclusions: Using appropriate self-report tools, patients share actual and potential modifiable barriers to adherence that can be addressed in clinical practice. Non-adherence behaviour was selective. Most non-adherence was driven by forgetfulness, concern about the harm caused by SPM and practical barriers.Keywords
Funding Information
- The Leeds Teaching Hospitals Charitable Foundation (Grant)
This publication has 33 references indexed in Scilit:
- Unintentional non-adherence to chronic prescription medications: How unintentional is it really?BMC Health Services Research, 2012
- Informed consent for interventions in stable coronary artery disease: problems, etiologies, and solutionsEuropean Journal of Cardio-Thoracic Surgery, 2011
- Adherence to Medicines in the Older-Aged with Chronic ConditionsDrugs & Aging, 2010
- Long-term persistence with statin treatment in a not-for-profit health maintenance organization: A population-based retrospective cohort study in IsraelClinical Therapeutics, 2008
- Medication-Taking for Coronary Artery Disease — Patients' PerspectivesEuropean Journal of Cardiovascular Nursing, 2008
- Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery diseaseAmerican Heart Journal, 2008
- Expected treatment benefits of percutaneous transluminal coronary angioplasty: the patient’s perspectiveThe International Journal of Cardiovascular Imaging, 2008
- Self-reported Medication Adherence and Cardiovascular Events in Patients With Stable Coronary Heart DiseaseThe Heart and Soul StudyArchives of internal medicine (1960), 2007
- Variations in Patients’ Adherence to Medical RecommendationsMedical Care, 2004
- Effectiveness of Interventions to Improve Patient ComplianceMedical Care, 1998